Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Junxi ^a   Au Yeung, Shiu Lun ^a   Lin, Shi Lin ^a   Leung, Gabriel M ^a   Schooling, C Mary ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE;

CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETICS; HEART MUSCLE ISCHEMIA; HUMAN; LIVER; MALE; MENDELIAN RANDOMIZATION ANALYSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MYOCARDIAL ISCHEMIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85006778370     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38813     Document Type: Article

References (50)

1. Fraser, A. et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arteriosclerosis, thrombosis, and vascular biology 27, 2729-2735, doi: 10.1161/ATVBAHA.107.152298 (2007).
2. Ghouri, N., Preiss, D. & Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology (Baltimore, Md.) 52, 1156-1161, doi: 10.1002/hep.23789 (2010).
3. Kunutsor, S. K., Abbasi, A. & Adler, A. I. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Annals of epidemiology 24, 809-816, doi: 10.1016/j.annepidem.2014.09.001 (2014).
4. Xu, L. et al. Liver enzymes and incident diabetes in China: a prospective analysis of 10 764 participants in the Guangzhou Biobank Cohort Study. Journal of epidemiology and community health 69, 1040-1044, doi: 10.1136/jech-2015-205518 (2015).
5. Sattar, N. et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53, 2855-2860 (2004).
6. Ford, I. et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and noncardiovascular outcomes. International journal of epidemiology 40, 1530-1538, doi: 10.1093/ije/dyr172 (2011).
7. Ruhl, C. E. & Everhart, J. E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136, 477-485 e411, doi: 10.1053/j.gastro.2008.10.052 (2009).
8. Kunutsor, S. K. et al. Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein. PloS one 10, e0132822, doi: 10.1371/journal.pone.0132822 (2015).
9. Malenica, M. et al. Use of Databases for Early Recognition of Risk of Diabetic Complication by Analysis of Liver Enzymes in Type 2 Diabetes Mellitus. Acta informatica medica: AIM: journal of the Society for Medical Informatics of Bosnia & Herzegovina: casopis Drustva za medicinsku informatiku BiH 24, 90-93, doi: 10.5455/aim.2016.24.90-93 (2016).
10. Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in medicine 27, 1133-1163, doi: 10.1002/sim.3034 (2008).
11. Goldberg, D. M., Martin, J. V. & Knight, A. H. Elevation of serum alkaline phosphatase activity and related enzymes in diabetes mellitus. Clinical biochemistry 10, 8-11 (1977).
12. Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature genetics 43, 333-338, doi: 10.1038/ng.784 (2011).
13. The Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nature genetics 43, 339-344, doi: 10.1038/ng.782 (2011).
14. The CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature genetics 45, 25-33, doi: 10.1038/ng.2480 (2013).
15. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature genetics 44, 981-990, doi: 10.1038/ng.2383 (2012).
16. Global Lipids Genetics, C. Discovery and refinement of loci associated with lipid levels. Nature genetics 45, 1274-1283, doi: 10.1038/ng.2797 http://www.nature.com/ng/journal/v45/n11/abs/ng.2797.html#supplementary-information (2013).
17. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature genetics 42, 105-116, doi: 10.1038/ng.520 (2010).
18. Chambers, J. C. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature genetics 43, 1131-1138, doi: 10.1038/ng.970 (2011).
19. Goessling, W. et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135, 1935-1944, 1944 e1931, doi: 10.1053/j.gastro.2008.09.018 (2008).
20. Taylor, A. E. et al. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. Economics and human biology 13, 99-106, doi: 10.1016/j.ehb.2013.12.002 (2014).
21. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997-1004 (1999).
22. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature genetics 47, 1121-1130, doi: 10.1038/ng.3396 (2015).
23. Soranzo, N. et al. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. Diabetes 59, 3229-3239, doi: 10.2337/db10-0502 (2010).
24. Burgess, S., Bowden, J., Fall, T., Ingelsson, E. & Thompson, S. G. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology (Cambridge, Mass.) (2016).
25. Human Protein Atlas available from www.proteinatlas.org.
26. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science (New York, N.Y.) 347, 1260419, doi: 10.1126/science.1260419 (2015).
27. Burtis, C. Tietz Textbook of Clinical Chemistry. (ER Ashwood. Philadelphia, WB Saunders Company, 1994).
28. Ashwood, B. a. Tietz NW: Textbook of Clinical Chemistry. Third edition edn, (PA, WB Saunders Company, Philadelphia, 1999).
29. Schooling, C. M., Kelvin, E. A. & Jones, H. E. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Annals of epidemiology 22, 789-798, doi: 10.1016/j.annepidem.2012.08.003 (2012).
30. Jacobs, M. et al. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metabolism: clinical and experimental 60, 969-975, doi: 10.1016/j.metabol.2010.09.006 (2011).
31. Lonardo, A., Lombardini, S., Ricchi, M., Scaglioni, F. & Loria, P. Review article: hepatic steatosis and insulin resistance. Alimentary pharmacology & therapeutics 22 Suppl 2, 64-70, doi: 10.1111/j.1365-2036.2005.02600.x (2005).
32. Tibi, L., Collier, A., Patrick, A. W., Clarke, B. F. & Smith, A. F. Plasma alkaline phosphatase isoenzymes in diabetes mellitus. Clinica chimica acta; international journal of clinical chemistry 177, 147-155 (1988).
33. Fall, T. et al. Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes. Diabetes 64, 2676-2684, doi: 10.2337/db14-1710 (2015).
34. Swerdlow, D. I. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet (London, England) 385, 351-361, doi: 10.1016/S0140-6736(14)61183-1 (2015).
35. Besseling, J., Kastelein, J. J., Defesche, J. C., Hutten, B. A. & Hovingh, G. K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. Jama 313, 1029-1036, doi: 10.1001/jama.2015.1206 (2015).
36. Schooling, C. M., Au Yeung, S. L. & Leung, G. M. Why do statins reduce cardiovascular disease more than other lipid modulating therapies? European journal of clinical investigation 44, 1135-1140, doi: 10.1111/eci.12342 (2014).
37. Pelletier, G. Localization of androgen and estrogen receptors in rat and primate tissues. Histology and histopathology 15, 1261-1270 (2000).
38. Tsuchiya, Y., Nakajima, M. & Yokoi, T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer letters 227, 115-124, doi: 10.1016/j.canlet.2004.10.007 (2005).
39. Chouinard, S. et al. Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. The Journal of steroid biochemistry and molecular biology 109, 247-253, doi: 10.1016/j.jsbmb.2008.03.016 (2008).
40. Raftogianis, R., Creveling, C., Weinshilboum, R. & Weisz, J. Chapter 6: Estrogen Metabolism by Conjugation. JNCI Monographs 2000, 113-124 (2000).
41. Margolis, K. L. et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47, 1175-1187, doi: 10.1007/s00125-004-1448-x (2004).
42. Hou, W. W., Tse, M. A., Lam, T. H., Leung, G. M. & Schooling, C. M. Adolescent testosterone, muscle mass and glucose metabolism: evidence from the 'Children of 1997' birth cohort in Hong Kong. Diabetic medicine: a journal of the British Diabetic Association 32, 505-512, doi: 10.1111/dme.12602 (2015).
43. Grossmann, M., Hoermann, R., Wittert, G. & Yeap, B. B. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clinical endocrinology 83, 344-351, doi: 10.1111/cen.12664 (2015).
44. Schooling, C. M. & Leung, G. M. Testosterone and cardiovascular risk. The lancet. Diabetes & endocrinology 3, 682, doi: 10.1016/S2213-8587(15)00281-8 (2015).
45. Banach, M. et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of medical science: AMS 11, 1-23, doi: 10.5114/aoms.2015.49807 (2015).
46. Schooling, C. M., Au Yeung, S. L., Freeman, G. & Cowling, B. J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC medicine 11, 57, doi: 10.1186/1741-7015-11-57 (2013).
47. Wald, A. The Fitting of Straight Lines if Both Variables are Subject to Error. The Annals of Mathematical Statistics 11, 284-300, doi: 10.1214/aoms/1177731868 (1940).
48. Fieller, E. C. Some Problems in Interval Estimation. Journal of the Royal Statistical Society. Series B: Methodological 16(2), 175-185 (1954).
49. Burgess, S. et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. European journal of epidemiology 30, 543-552, doi: 10.1007/s10654-015-0011-z (2015).
50. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 40, 304-314, doi: 10.1002/gepi.21965 (2016).